TD Cowen analyst Brendan Smith lowered the firm’s price target on Ginkgo Bioworks (DNA) to $12 from $16 and keeps a Buy rating on the shares. The firm said the Q4 miss and light FY25 guide driven by government contract exposure and slower biotech spending; though newer Tools/AI offerings could drive upside.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNA:
- Cautious Outlook on Ginkgo Bioworks: Sell Rating Amid Financial and Strategic Concerns
- Ginkgo Bioworks Holdings: Buy Rating Affirmed Amid Growth Potential in Tools and AI Offerings Despite Price Target Reduction
- Ginkgo Bioworks Reports Improved Q4 2024 Results
- Ginkgo Bioworks sees FY25 revenue $160M-$180M, consensus $203.81M
- Ginkgo Bioworks reports Q4 EPS ($2.00), consensus ($1.30)